ASH21

BeyondSpring's New Plinabulin Data Shows Fast Onset In Preventing Chemo-Induced Neutropenia

Global Blood Raises $300M Via Convertible Debt Offering

Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients

Global Blood Raises $300M Via Convertible Debt Offering

Roche's Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients

Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients

Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden

Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients

Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients

ASH21 Recent News

Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update

Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in

Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma

Fate Therapeutics Inc (NASDAQ: FATE)

Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD),

Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial

Syndax Pharmaceuticals Inc (NASDAQ: SNDX)

ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation

ALX Oncology Holdings Inc (NASDAQ: ALXO) presented

Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?

X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares are trading lower despite releasing what it described as

Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation

Viracta Therapeutics Inc (NASDAQ: VIRX)

Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients

Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively.

Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet

Harpoon Therapeutics Inc (NASDAQ: HARP) presented a poster with

JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted

What Analysts Have To Say On Incremental IGM-2323 Data At ASH Presentation

IGM Biosciences Inc (NASDAQ: IGMS) shares plunged

IGM Biosciences' B Cell Malignancies Trial Data Fails To Lift The Stock

IGM Biosciences Inc (NASDAQ: IGMS) has

Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting

Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells,

New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment

Bluebird Bio Inc (NASDAQ: BLUE)

Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program

Bluebird bio Inc (NASDAQ: BLUE)

Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients

Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced

Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting

Bristol Myers Squibb & Co (NYSE: BMY)